1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Drugs In Development, 2022, provides an overview of the Colon Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 31, 60, 2, 12, 246, 44 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 42 and 12 molecules, respectively.
Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Colon Cancer - Overview
- Colon Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Colon Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Colon Cancer - Companies Involved in Therapeutics Development
- Colon Cancer - Drug Profiles
- Colon Cancer - Dormant Projects
- Colon Cancer - Discontinued Products
- Colon Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Colon Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Colon Cancer - Dormant Projects, 2022
- Colon Cancer - Discontinued Products, 2022
- Number of Products under Development for Colon Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- ABL Bio Inc
- ABM Therapeutics Inc
- Abologix Sarl
- Acomhal Research Inc
- Actinium Pharmaceuticals Inc
- Actym Therapeutics Inc
- Adagene Suzhou Ltd
- Advenchen Laboratories LLC
- Adze Biotechnology Inc
- Affimed GmbH
- Agastiya Biotech LLC
- AgomAb Therapeutics NV
- AI Therapeutics Inc
- AIGEN Sciences Inc
- Alaunos Therapeutics Inc
- Alligator Bioscience AB
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Alyra Therapeutics Inc
- Amgen Inc
- Amrita Therapeutics
- ANP Technologies Inc
- Antibody Therapeutics Inc
- Aphios Corp
- Apollomics Inc
- AptaBio Therapeutics Inc
- Arbutus Biopharma Corp
- Ardan Pharma
- Ariz Precision Medicine Inc
- Ascelia Pharma AB
- Ascendis Pharma AS
- Ascendo Biotechnology Inc
- Ascentawits Pharmaceuticals Ltd
- AskAt Inc
- Asylia Therapeutics Inc
- aTyr Pharma Inc
- Aucentra Therapeutics Pty Ltd
- Aurigene Discovery Technologies Ltd
- Avican Inc
- Avidin Biotechnology Ltd
- Avidity Biosciences Inc
- Azanta A/S
- Bayer AG
- Baylx Inc
- BeiGene Ltd
- Beijing FuKangren Bio-pharm Tech Co Ltd
- Beijing Weiyuan Likang Biological Technology Co Ltd
- BenoBio Co Ltd
- BeyondSpring Inc
- Binjiang Pharma, Inc.
- BioAtla Inc
- Biocytogen Pharmaceuticals (Beijing) Co Ltd
- Biogazelle NV
- BioMed Valley Discoveries Inc
- Biomunex Pharmaceuticals
- BioXpress Therapeutics SA
- Bliss Biopharmaceutical (Hangzhou) Co Ltd
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- BoYen Therapeutics Inc
- Bristol-Myers Squibb Co
- Calidi Biotherapeutics Inc
- Can-Fite BioPharma Ltd
- CanBas Co Ltd
- Cancure Ltd
- Canget BioTekpharma LLC
- Cantargia AB
- Carina Biotech Pty Ltd
- CEFO Co Ltd
- Celldex Therapeutics Inc
- Cellective BioTherapy Inc
- Celprogen Inc
- Center for Genetic Engineering and Biotechnology
- Centrymed Pharmaceutical Inc
- Changchun Huapu Biotechnology Co Ltd
- Chengdu Huitai Biomedicine Co Ltd
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chinook Therapeutics Inc
- Claradele Pharmaceuticals Inc
- CMG Pharmaceutical Co Ltd
- CNCure Biotech Inc
- Coastar Therapeutics LLC
- Codiak BioSciences Inc
- Coherent Biopharma
- Cosmo Pharmaceuticals NV
- CStone Pharmaceuticals Co Ltd
- Cureport Inc
- CV6 Therapeutics (Ni) Ltd
- Cytodyn Inc
- CytomX Therapeutics Inc
- CZ BioMed Corp
- Defence Therapeutics Inc
- DEKK-TEC Inc
- Diazon Pharmaceuticals Inc
- DiNonA Inc
- Disulfican Ltd
- Diverse Biotech Inc
- Dracen Pharmaceuticals Inc
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- Duet Therapeutics Inc
- eFFECTOR Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Elicera Therapeutics AB
- Elixiron Immunotherapeutics Inc
- Elucida Oncology Inc
- Emcure Pharmaceuticals Ltd
- Enara Bio Ltd
- EncuraGen Co Ltd
- Enochian Biosciences Inc
- EnzymeBioSystems
- Epigene Therapeutics Inc
- Eucure (Beijing) Biopharma Co Ltd
- Evestra Inc
- Evgen Pharma Plc
- Evopoint Bioscience Co Ltd
- F. Hoffmann-La Roche Ltd
- Felicitex Therapeutics Inc
- For-Robin Inc
- Frontbio Co Ltd
- Fujifilm Holdings Corp
- GC Biopharma Corp
- GeneLeap Biotech
- Genexine Inc
- GeoVax Labs Inc
- Ginkgo BioWorks Inc
- GlycaNova AS
- GlyTR Therapeutics Inc
- GO Therapeutics Inc
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- HaimBio Ltd
- Hamlet Pharma AB
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- Horizon Therapeutics Plc
- Hummingbird Bioscience Pte Ltd
- i2 Pharmaceuticals Inc
- Ikena Oncology Inc
- Ildong Pharmaceutical Co Ltd
- ImCheck Therapeutics SAS
- Immix BioPharma Inc
- Immune Modulation Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- Immunos Therapeutics AG
- Immvira Co Ltd
- IMPACT Therapeutics Inc
- Imugene Ltd
- inCerebro Co Ltd
- Infinity Pharmaceuticals Inc
- Inmune Bio Inc
- Innate Pharma SA
- InnoCare Pharma Ltd
- Innopharmax Inc
- Intensity Therapeutics Inc
- iOmx Therapeutics AG
- iOnctura SA
- Ipsen SA
- Ix Therapeutics GmbH
- J-Pharma Co Ltd
- JenKem Technology Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Jina Pharmaceuticals Inc
- JN Biosciences LLC
- Jubilant Therapeutics Inc
- JW Pharmaceutical Corp
- Kadmon Holdings Inc
- KAHR medical Ltd
- Kazia Therapeutics Ltd
- Kintara Therapeutics Inc
- Kringle Pharma Inc
- Laekna Therapeutics Shanghai Co Ltd
- Linnane Pharma AB
- LipoSeuticals Inc
- Lixte Biotechnology Holdings Inc
- Luzitin SA
- Machavert Pharmaceuticals LLC
- MacroGenics Inc
- Marine Biomedical Research Institute of Qingdao
- MaxiVAX SA
- Medicenna Therapeutics Corp
- Medicon Pharmaceuticals Inc
- Medigen Biotechnology Corp
- MedPacto Inc
- Mendus AB
- Merck & Co Inc
- MicroQuin Ltd
- Midissia Therapeutics Inc
- Mito BioPharm LLC
- Mosaic ImmunoEngineering Inc
- Multimmune GmbH
- MultiVir Inc
- Myeloid Therapeutics Inc
- Nammi Therapeutics Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- Nascent Biotech Inc
- NED Biosystems Inc
- Nektar Therapeutics
- Netris Pharma SAS
- Nimbus Therapeutics LLC
- Novartis AG
- Nutshell Therapeutics Inc
- OBiO Technology (Shanghai) Corp Ltd
- Oceanyx Pharmaceuticals Inc
- Oita University Institute of Advanced Medicine Inc
- Omeros Corp
- Oncocross Co Ltd
- Oncology Pharma Inc
- Oncolyze Inc
- Oncovir Inc
- Oncoxx Biotech Srl
- Oneness Biotech Co Ltd
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- Orpheus Therapeutics Inc
- Oryn Therapeutics
- Pacylex Pharmaceuticals Inc
- Papyrus Therapeutics Inc
- Parasol Biotech Co Ltd
- Pathios Therapeutics Ltd
- Patrys Ltd
- PAZ Pharma
- Pfizer Inc
- PharmAbcine Inc
- Phenex Pharmaceuticals AG
- Phio Pharmaceuticals Corp
- Photolitec LLC
- PHusis Therapeutics Inc
- Pionyr Immunotherapeutics Inc
- PNB Vesper Life Science Pvt Ltd
- PolyPid Ltd
- Portage Biotech Inc
- Primetime Life Sciences LLC
- Propanc Biopharma Inc
- Prosetta Biosciences Inc
- Protexase Therapeutics Inc
- Provecs Medical GmbH
- Provectus Biopharmaceuticals Inc
- PsiOxus Therapeutics Ltd
- PTM Therapeutics Inc
- Pylum Biosciences Inc
- Qilu Puget Sound Biotherapeutics Corp
- Qu Biologics Inc
- Ranger Biotechnologies AS
- Riptide Bioscience Inc
- Sagimet Biosciences Inc
- Sanofi
- Sareum Holdings Plc
- Savoy Pharmaceuticals Inc
- Schrodinger Inc
- SEEKYO Therapeutics
- Senex Biotechnology
- SetLance srl
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai GeneChem Co Ltd
- Shattuck Labs Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Shionogi & Co Ltd
- Sichuan Huiyang Life Science and Technology Corp
- SideROS
- SignPath Pharma Inc
- Simcere Pharmaceutical Group Ltd
- SIRPant Immunotherapeutics Inc
- Somantix BV (Inactive)
- Soricimed Biopharma Inc
- Sorrento Therapeutics Inc
- SOTIO Biotech AS
- Sparx Therapeutics Inc
- Sphaera Pharma Pte Ltd
- Statera Biopharma Inc
- Stcube Inc
- Stingray Therapeutics LLC
- Sumitomo Pharma Co Ltd
- Suzhou Stainwei Biotech Inc
- Syncromune Inc
- TAE Life Sciences LLC
- Taiho Pharmaceutical Co Ltd
- Takis Srl
- Tango Therapeutics Inc
- TargaGenix Inc
- Tarus Therapeutics Inc
- TenCure Ltd
- TheraBioPharma Inc
- Theravectys SA
- Tianjin Hengjia Biotechnology Development Co Ltd
- Tiziana Life Sciences Plc
- Toray Industries Inc
- Totus Medicines Inc
- Transcenta Holding Ltd
- Transgene Biotek Ltd
- TVAX Biomedical Inc
- Twist Bioscience Corp
- Tychon Bioscience Inc
- Tyg Oncology Ltd
- Tyme Inc
- United Immunity Co Ltd
- Vascular Biogenics Ltd
- Vault Pharma Inc
- Viomedix LLC
- Viracta Therapeutics Inc
- Virocure Inc
- Virogin Biotech Ltd
- WellMarker Bio Co Ltd
- Werewolf Therapeutics Inc
- Westwood Bioscience Inc
- WindMIL Therapeutics Inc
- WntResearch AB
- Wuhan YZY Biopharma Co Ltd
- Wuxi Zhikang Hongyi Biological Technology Co Ltd
- XOMA Corp
- Y-mAbs Therapeutics Inc
- Yuhan Corp
- Zenith Epigenetics Ltd
- Zovis Pharmaceuticals
